Xiromed debuts 2 generics
Xiromed is introducing two generics.
The company is rolling out Guanfacine Tablets, 1 mg and 2 mg strengths, which is the generic of Tenex.
Generic Tenex is used alone or with other medications to treat high blood pressure, also known as hypertension, and will be available in 100-count bottles.
[Read more: Xiromed, Genzum unveil generic Naftin]
Tenex and its generics had a market value of $35 million, for the 12 months ending in January per IQVIA.
“Xiromed continues to bring affordable generic options to market for U.S. patients. The launch of Guanfacine tablets bolsters our portfolio of high-quality generic medicines as we continue to expand Xiromed’s footprint in the U.S. pharmaceutical market,” said Xiromed CEO Rob Spina.
In addition, the company also is launching Ganirelix Acetate Injection 250mcg/0.5ml Pre-Filled Syringe—a generic of Organon Pharmaceutical’s Ganirelix Acetate Injection.
The medication is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.
Ganirelix Acetate Injection had a market value of $88.2 million for the 12 months ending in January 2024, per IQVIA.
[Read more: Xiromed unveils generic Extina]
“I am thrilled to announce the launch of our Ganirelix Acetate Injection product. As a leading provider of women’s healthcare products globally and in the United States, we are excited to further expand our offerings into the fertility space. The use of assisted reproductive technology has grown significantly over the past decade, yet the cost burden on patients continues to be a barrier to access. At Xiromed, we are excited to offer a high-quality and an affordable option to patients and their providers to improve access and provide additional choices in family planning,” said Spina.